Market Overview

CryoLife Enters into Worldwide Distribution and Manufacturing Agreements

CryoLife, Inc. (NYSE: CRY) announced today that it has entered into a worldwide distribution agreement and a manufacturing agreement with Starch Medical Inc. (SMI) of San Jose, California for PerClot®, a novel polysaccharide hemostatic agent used in surgery.

The U.S. hemostatic market is estimated to be $732 million in 2010 growing to approximately $1.1 billion in 2014, while the European market is estimated to be $279 million in 2010 growing to approximately $430 million in 2014.(1)

Posted-In: News Contracts

 

Related Articles (CRY + SMI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters